Levels of circulating ECD/HER-2 are easily detectable in the serum of breast cancer patients and its measurement has been proved useful to monitor women with metastatic breast cancer, to detect the early appearance of recurrent breast cancer and to predict response to hormonal therapy or chemotherapy [25,26]. Here, ERBB2 is linked to breast carcinoma.